Evidence map›Paper›PMID 40129890›Full record

ArticleInternational journal of translational medicine (Basel, Switzerland)2024

A Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early Diagnosis and Prognostication.

Martin Tobi, Harvinder Talwar, Noreen F Rossi, Warren Lockette, Benita McVicker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of translational medicine (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin TobiDepartment of Research and Development, Detroit VAMC, 4646 John R Street, Detroit, MI 48601, USA.
Harvinder TalwarDepartment of Research and Development, Wayne State University School of Medicine, Detroit VAMC, 4747 John R Street, Detroit, MI 48602, USA.
Noreen F RossiDivision of Nephrology, Department of Internal Medicine, Research and Development, Wayne State University School of Medicine, Detroit VAMC, 4646 John R Street, Detroit, MI 48601, USA.
Warren LocketteDivision of Endocrinology, Department of Internal Medicine, Research and Development, Wayne State University School of Medicine, Detroit VAMC, 4646 John R Street, Detroit, MI 48601, USA.
Benita McVickerResearch Service, VA Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, NE 68105, USA.

Funding

BLRD VA I01 BX004127
6 · The paper itself

Abstract

Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions. BACKGROUND/

objectivesRecently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications.

methodsWe have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication.

resultsThese InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means.

conclusionsThe FERAD (ferritin-fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.

Indexed as

absolute neutrophil/lymphocyte ratioAdnab-9cancer constellationsFERAD ratiop87PD-L1 treatment outcomes

Identifiers

PMID40129890
PMCPMC11931686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.